

A complete diagnostic solution to screen for multiple myeloma

Guidelines recommend sFLC tests alongside SPEP and sIFE to gain greater diagnostic sensitivity. 1-3

Clinical sensitivity of monoclonal gammopathy detection by various methods.⁴

Diagnosis %	sFLC	SPE	sIFE	MGP
Multiple Myeloma	96.8	87.6	94.4	100.0
Macroglobulinemia	73.1	100.0	100.0	100.0
Smoldering MM	81.2	94.2	98.4	100.0
MGUS	42.4	81.9	92.8	97.1

n = 1,877

Freelite® Test Results:5

Freelite® tests provide two values:

- The concentration of kappa and lambda light chains.
- The kappa/lambda ratio.

An abnormal kappa/lambda ratio is a sensitive marker of plasma cell clonality.¹

Serum Free Light Chain Reference Intervals					
Normal Adult Serum Central 95th Percentile					
3.30-19.40 mg/L					
5.71-26.30 mg/L					
0.26-1.65	Ratio >1.65				
Normal Ratio	Normal Ratio Abnormal Ratio				
	3.3 5.7 0.26-1.65				

How to Order:

Test Code	Short Test Name	Full Test Name	Specimen Requirements
804319	MGP	Monoclonal Gammopathy Dx Panel (SPE, TP, sFLC, IT)	SST, 2 mL serum
804320	MGP w/Reflex IT	Monoclonal Gammopathy Dx Panel w/Reflex IT (SPE, TP, sFLC)	SST, 2 mL serum
804321	MGPA	Monoclonal Gammopathy Dx Panel, AL Amy (SPE, TP, sFLC, IT, uIFE)	SST, 2 mL serum: 4 mL urine
9199	ProfSPE and IFE	Monoclonal Gammopathy Monitoring Panel (SPE, IT)	SST, 2 mL serum

Individual components can be ordered separately: Protein, Total - 1020; IT Interpretation - 3037; Free Kappa/Lambda L/C Ratio, Serum - 903371; Protein Electrophoreses, Serum - 2075; Protein, Urine, Random, Normalized - 2482; Urine IFE Interpretative, Random - 9245; Immunoglobulin Quantitative - 1430.

CPT Codes:^a

83521 (x2)	Free Light Chain Kappa and Lambda (sFLC)
84165	Serum Protein Electrophoresis (SPEP)
86320	Serum Immunofixation Electrophoresis (sIFE)

aThe CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.



Talk to your Sonora Quest Account Manager to learn more about multiple myeloma panels.

REFERENCES:

- 1. Dispenzieri A et al. International Myeloma Working Group Guidelines for serum free light chains in multiple myeloma and other related disorders, Leukemia 2009;23:215
 2. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology® for Multiple Myeloma 2023. © National Comprehensive Cancer Network, Inc 2022. All rights reserved. Accessed January 2023. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc
- 3. Keren DF et al. Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology. Arch Pathol Lab Med 2021;146:575-90
- 4. Katzmann, JA, Kyle, RA, et al. 2009. "Screening panels for the detection of monoclonal gammopathies." Clinical Chemistry 55(8): 1517-1522
- 5. Optilite® Freelite® Kappa Free Kit INS016.0PT.A & Optilite® Freelite® Lambda Free Kit INS018.0PT.A, Version: 17th June 2015

Freelite® is a registered trademark of The Binding Site Group Ltd. (Birmingham, UK) in certain countries.

SonoraQuest.com

